

# Effectiveness and waning of protection with different SARS-CoV-2 primary and booster vaccines during the Delta pandemic wave in 2021 in Hungary (HUN-VE 3 study)

1

2

Zoltán Vokó<sup>1,2\*†</sup>, Zoltán Kiss<sup>3†</sup>, György Surján<sup>4,5</sup>, Orsolya Surján<sup>6</sup>, Zsófia Barcza<sup>7</sup>, István Wittmann<sup>3</sup>, Gergő Attila Molnár<sup>3</sup>, Dávid Nagy<sup>1,2</sup>, Veronika Müller<sup>8</sup>, Krisztina Bogos<sup>9</sup>, Péter Nagy<sup>10,11</sup>, István Kenessey<sup>10,12</sup>, András Wéber<sup>10,13</sup>, Lőrinc Polivka<sup>8</sup>, Mihály Pálosi<sup>15</sup>, János Szlávik<sup>16</sup>, György Rokszin<sup>3,17</sup>, Cecília Müller<sup>18</sup>, Zoltán Szekanecz<sup>19††</sup>, Miklós Kásler<sup>4††</sup> 3

- 4
- <sup>1</sup>Center for Health Technology Assessment, Semmelweis University, Budapest 5
- 6 <sup>2</sup>Syreon Research Institute, Budapest, Hungary
- 7 <sup>3</sup>Second Department of Medicine and Nephrology-Diabetes Center, University of Pécs Medical School, Pécs, Hungary 8
- <sup>4</sup>Ministry of Human Resources, Budapest, Hungary 9
- <sup>5</sup> Institute of Digital Health Sciences, Semmelweis University, Budapest 10
- <sup>6</sup>Department of Deputy Chief Medical Officer II., National Public Health Center, Budapest, Hungary 11
- <sup>7</sup>Syntesia Medical Communications Ltd., Budapest, Hungary 12
- 13 <sup>8</sup>Department of Pulmonology, Semmelweis University, Budapest, Hungary
- 14 <sup>9</sup>Department of Pulmonology, National Korányi Institute of Pulmonology, Budapest, Hungary
- <sup>10</sup>National Institute of Oncology, Budapest, Hungary 15
- <sup>11</sup>Institute of Oncochemistry, University of Debrecen, 4012 Debrecen, Hungary 16
- 17 <sup>12</sup>Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest,
- 18 Hungary
- 19 <sup>13</sup>Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France
- 20 <sup>14</sup>Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, 21 Hungary
- 22 <sup>15</sup>National Health Insurance Fund, Budapest, Hungary
- <sup>16</sup>South-Pest Hospital Centre National Institute for Infectology and Haematology, Budapest, 23 24 Hungary
- <sup>17</sup>RxTarget Ltd., Szolnok, Hungary 25
- <sup>18</sup>Department of Chief Medical Officer, National Public Health Center, Budapest, Hungary 26

<sup>19</sup>Department of Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary

### 28 \* Correspondence:

- 29 Prof. Dr. Zoltan Vokó;
- 30 Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary; H-1091
- 31 Budapest Üllői út 25., phone: +36 30 992 7628;
- 32 email: voko.zoltan@semmelweis-univ.hu
- <sup>†</sup> These authors contributed equally to this work and share first authorship
- <sup>††</sup> These authors contributed equally to this work and share senior authorship

Keywords: Booster vaccine, Delta variant, Vaccine effectiveness, Sinopharm, Sputnik-V,
 Janssen, Covid-19

37 Abstract

38 Background: In late 2021, the pandemic wave was dominated by the Delta SARS-CoV-2 variant in

39 Hungary. Booster vaccines were offered starting from August 2021.

40 Methods: The nationwide HUN-VE 3 study examined the effectiveness and durability of primary

41 immunization and single booster vaccinations on SARS-CoV-2-related infection, hospitalization and

42 mortality during the Delta wave.

43 Results: The study population included 8,087,988 individuals aged 18–100 years at the beginning of 44 the pandemic. During the Delta wave, after adjusting for age, sex, calendar day, and chronic diseases, 45 vaccine effectiveness (VE) of primary vaccination against registered SARS-CoV-2 infection was between 11% to 77% and 18% to 79% 14–120 days after primary immunization in the 16–64 and 46 47 65–100 years age cohort respectively, while it decreased to close to zero in the younger age group 48 and around 40% or somewhat less in the elderly after 6 months for almost all vaccine types. In the 49 population aged 65–100 years, we found high, 88.1%–92.5% adjusted effectiveness against Covid-19 50 infection after the Pfizer-BioNTech, and 92.2%-95.6% after the Moderna booster dose, while 51 Sinopharm and Janssen booster doses provided 26.5%–75.3% and 72.9%–100.0% adjusted VE, 52 respectively. Adjusted VE against Covid-19 related hospitalization was high within 14–120 days for 53 Pfizer-BioNTech: 76.6%, Moderna: 83.8%, Sputnik-V: 78.3%, AstraZeneca: 73.8%, while modest 54 for Sinopharm: 45.7% and Janssen: 26.4%. The waning of protection against Covid-19 related 55 hospitalization was modest and booster vaccination with mRNA vaccines or the Janssen vaccine 56 increased adjusted VE up to almost 100%, while the Sinopharm booster dose proved to be less 57 effective. VE against Covid-19 related death after primary immunization was high or moderate: for 58 Pfizer-BioNTech: 81.5%, Moderna: 93.2%, Sputnik-V: 100.0%, AstraZeneca: 84.8%, Sinopharm: 59 58.6%, Janssen: 53.3%). VE against this outcome also showed moderate decline over time, while 60 booster vaccines restored effectiveness up to almost 100%, except for the Sinopharm booster.

61 Conclusions: The HUN-VE 3 study demonstrated waning VE with all vaccine types for all examined

62 outcomes during the Delta wave and confirmed the outstanding benefit of booster vaccination with

63 the mRNA or Janssen vaccines. This is the first study to provide comparable effectiveness results for

64 six different booster types during the Delta pandemic wave.

### 65 **1 Introduction**

66 In Hungary, six different SARS-CoV-2 vaccines were approved in the first half of 2021, and five of

67 them were investigated and showed high or very high short-term effectiveness against SARS-CoV-2

68 infection (Alpha variant) and Covid-19 related mortality in the nationwide HUN-VE 1 study (1). In

69 the second half of 2021, a growing number of studies started reporting a waning effectiveness for

vaccines over time, especially against the new, more infectious Delta variant and to less extent

- against Covid-19 related death (B.1.617.2) (2,3,4,5,6). To maintain protection against emerging new
- waves and variants, several European countries including Hungary started offering booster vaccine
- doses in summer 2021 (7,8). The benefit of booster vaccination has been demonstrated by a number

of recent studies (9,10,11). On August 1, 2021, the Hungarian government introduced the option of a

booster dose with one of six vaccine types at least 4 months after primary immunization, particularly

- 76 for the vulnerable population such as people aged 60 years or older and those having chronic
- 77 illnesses (12).
- 78 The aim of our study was to estimate the effectiveness of six different vaccine types as well as their
- 79 combinations as primary or booster vaccines against SARS-CoV-2 infection, Covid-19 related
- 80 hospitalization and death during the Delta pandemic wave between September 2021 and December
- 81 2021 in Hungary. We also aimed to evaluate the durability of protection offered by vaccine
- 82 combinations to provide guidance for countries where multiple vaccine types are available.

## 83 2 Methods

84 The study population included Hungarian residents aged 18 to 100 years who were registered in the

85 Hungarian-COVID-19 Registry based on the National Public Health Center (NPHC) and National

86 Health Insurance Fund Manager (NHIFM) database on March 4, 2020, when the first case of Covid-

87 19 infection was detected in Hungary. Exclusion criteria included any inconsistencies in data such as

88 a person receiving two different vaccine types for primary immunization, missing information on the

89 type of the second vaccine dose, first vaccination administered before the first potential date of

administration, fewer than 14 days between the first and second doses, a date of diagnosis before the
 first case was officially reported, or a date of death preceding the date of first vaccination. Fewer than

92 1.000 cases were excluded for reasons other than age outside the predefined range.

93 Cases of SARS-CoV-2 infection were reported on a daily basis using a centralized system via the

94 National Public Health Center (NPHC). The report is based on (i) Covid-19-related symptoms

95 identified by hospital physicians and general practitioners, (ii) positive nucleic acid amplification test

96 reported by microbiological laboratories. Cases identified by symptoms were confirmed by PCR or

97 antigen test included in the EC rapid test list (13). Covid-19 related hospitalization was defined as

- 98 hospitalization with a positive PCR or antigen test within 5 days before or 20 days after admission to
- 99 hospital. Covid-19 related mortality was defined as death during SARS-CoV-2 positivity without
- 100 previously declared recovery and without another clear cause of death (e.g., accident, suicide). The
- 101 definition was based on WHO recommendations and defined by the healthcare government (14).
- 102 Individuals were classified as primary vaccinated if at least 14 days had passed since the
- administration of the second dose of the BNT162b2 (Pfizer-BioNTech), HB02 (Sinopharm), Gam-
- 104 COVID-Vac (Sputnik-V), AZD1222 (AstraZeneca), or mRNA-1273 (Moderna) vaccines, or the first

105 dose of Ad26.COV2.S (Janssen). At any time point during the study period, the unvaccinated, control

106 population included individuals who had not received any dose of any Covid-19 vaccine type

107 beforehand.

- 108 Vaccine effectiveness (VE) was defined as 1 minus the incidence rate ratio of the outcome in
- 109 question. Vaccine combinations administered to at least 3,000 people by December 31, 2021 or with
- at least 300 cases from the start of the pandemic until December 31, 2021 in Hungary were included
- 111 in the analysis. Vaccine combinations were further broken down into subcategories according to the
- time elapsed since their administration. These subcategories were defined as 14–120, 121–180, 181–
- 113 240, or more than 240 days. For booster vaccinations, only the 14–120 days category was
- established, because there were very few individuals during the Delta wave who had received their
- 115 booster vaccination more than 120 days earlier.
- All Hungarian residents aged 18–100 years who were registered in the NHIFM on March 4, 2020
- 117 were considered unvaccinated and uninfected persons apart from the first identified cases of Covid-
- 118 19 infection. For each day afterwards until the end of the study period, we calculated the number of
- 119 individuals at risk for different groups by age, sex, history of certain chronic diseases and
- 120 vaccination, taking into account the types of vaccines and the time elapsed since their administration
- 121 (intervention). Individuals who died were removed from the study base. The numbers of new
- registered infections, COVID-19 related hospitalizations, and deaths were registered for each day
- according to intervention, and individuals experiencing an outcome were removed from the study
- 124 population of the respective analysis. Person-days for each intervention group were calculated by
- 125 adding up the number of persons in each group for each day.
- 126 Age was categorized as 18–24, 25–34, 35–44, 45–54, 55–64, 65–74, 75–84, and 85–100 years. The
- presence of chronic diseases was identified based on in- and outpatient health service utilization and
- prescription data from the NHIFM between January 1, 2013 and March 3, 2021. The following
- 129 chronic conditions were considered: cardiovascular diseases (myocardial infarction, angina, chronic
- 130 heart failure, peripheral vascular disease, and stroke), diabetes mellitus (type 1 and type 2),
- 131 immunosuppression (immunosuppressive therapy and transplantation), chronic pulmonary diseases
- 132 (asthma and chronic obstructive pulmonary diseases), neoplasms, and chronic kidney diseases. The
- 133 definitions of chronic diseases are presented in Supplementary Table 1.
- 134 Incidence rates (number of outcomes divided by person-time of observation) together with their exact
- 135 95% confidence intervals (CIs) were calculated for the period between September 13, 2021 and
- 136 December 31, 2021 (Delta wave). Rate ratios with their exact confidence intervals were obtained
- 137 considering unvaccinated as the reference category, using STATA (version 16.1).
- 138 Mixed effect negative binomial regression model was used to derive adjusted incidence rate ratios
- 139 (IRRs) with 95% CIs for each outcome adjusted for age, sex, history of different chronic diseases,
- 140 and calendar day (modelled as a random effect), which is better suited for over-dispersed count data
- 141 than the traditional Poisson regression. The model is a random intercept model, which allows for
- 142 different incidence rates in the reference category (i.e., unvaccinated) each day, but assumes fixed
- 143 effect of the intervention categories. Separate models were fitted to estimate age group specific
- 144 effects (i.e., 18–64 years and 65–100 years).
- The study was approved by the Central Ethical Committee of Hungary (OGYÉI/10296-1/2022 and
  IV/1722- 1/2022/EKU).

## 147 **3 Results**

- 148 The study population included 8,087,988 individuals (18-64 years: n=6,193,552, 65-100 years:
- 149 n=1,894,436) at the beginning of the pandemic.

- **Running Title**
- 150 In the age group of 16–64 years, the crude incidence rate of SARS-CoV-2 infection was 67.6 per
- 151 100,000 person-days in the unvaccinated cohort during the Delta wave. In the primary vaccination
- cohorts, crude incidence rates varied between 5.2 and 38.3 per 100,000 person-days after 14-120 152
- 153 days of the second vaccine dose (Supplementary Table 2). Crude incidence rates of infection
- 154 progressively increased 120-180, 181-240 and >240 days after the second vaccine dose for each
- 155 vaccine type, even exceeding crude incidence rates of the unvaccinated population 6 months after
- 156 primary vaccination. On the other hand, after booster vaccination with the Pfizer-BioNTech,
- 157 Moderna or Janssen vaccines, crude incidence rates fell below 20 per 100,000 person-days,
- 158 regardless of the type of vaccines used for primary immunization except for the Sputnik-V, Sputnik-159
- V, Janssen combination. On the other hand, booster vaccination with the Sinopharm vaccine resulted
- 160 in crude incidence rates of 25.2–61.2 per 100,000 person-days, depending on the type of the primary
- 161 vaccination (Supplementary Table 2).
- 162 Similar results were seen in the 65-100 years age cohort: lower crude incidence rates of SARS-CoV-
- 163 2 infection 14–120 days after primary vaccination for each vaccine type compared to the
- unvaccinated cohort (54.8 per 100,000 person-days), increasing infection rates after 4 months, and 164
- 165 very low rates (<10 per 100,000 person-days) after booster vaccination with mRNA vaccines,
- 166 regardless of primary vaccine types (Supplementary Table 3).
- 167 Higher effectiveness and slightly less waning of protection were found against Covid-19 related
- 168 hospitalization and death in both age groups. However, both hospitalization and mortality rates were
- close to respective rates in the unvaccinated cohort 240 days after the second vaccine dose for most 169
- 170 vaccine types, while booster vaccination led to relevant decreases in the incidence rates of these
- 171 outcomes (Supplementary Tables 4–7).
- After adjusting for age, sex, chronic diseases, and calendar day, vaccine effectiveness of primary 172
- 173 vaccination against SARS-CoV-2 infection varied between 10.9% and 76.9% 14-120 days after the
- 174 second dose in the 16–64 years age cohort (Figure 1A), and between 17.8% and 79.1% in the 65–100
- 175 years age cohort (Figure 2A). Adjusted vaccine effectiveness decreased to close to zero in the
- 176 younger age group and around 40% or somewhat less in the elderly after 6 months for almost all 177 vaccine types. In the population aged 65-100 years, we found high, 88.1%-92.5% adjusted
- 178 effectiveness against Covid-19 infection after the Pfizer-BioNTech booster dose, and 92.2%-95.6%
- 179 adjusted effectiveness after the Moderna booster during the first 4 months after booster
- 180 immunization. The Sinopharm and Janssen boosters provided 26.5%–75.3% and 72.9%–100.00%
- 181 adjusted effectiveness, respectively, depending on primary immunization type (Figure 1A and 2A,
- 182 Supplementary Table 3).
- 183 In the primary immunized population aged 65–100 years, adjusted vaccine effectiveness against
- 184 Covid-19 related hospitalization was 76.6% with the Pfizer-BioNTech, 83.8% with the Moderna,
- 185 78.3% with the Sputnik-V, 73.8% with the AstraZeneca, 45.7% with the Sinopharm, and 26.4%
- 186 with the Janssen vaccine within 14–120 days after the second dose (Figure 2B, Supplementary Table
- 187 5). The waning of protection against Covid-19 related hospitalization was much less pronounced than
- 188 against SARS-CoV-2 infection. Nevertheless, after more than 240 days, primary Pfizer-BioNTech,
- 189 Moderna, Sputnik-V, and Sinopharm vaccinations had lost around 20% of their effectiveness in
- 190 relative terms against Covid-19 related hospitalization. Booster vaccination with mRNA vaccines or
- 191 the Janssen vaccine increased adjusted effectiveness up to almost 100% (92.1% to 97.6% for Pfizer-
- 192 BioNTech booster, 94.8% to 98.3% for Moderna booster and 90.00% to 100.00% for Janssen booster
- 193 doses) irrespective of the vaccine type used for primary immunization, while the Sinopharm booster
- 194 dose proved to be less effective in this regard (57.1% to 86.7%) (Figure 2B, Supplementary Table 5).

### 195

- 196 In individuals aged 65–100 years, vaccine effectiveness against Covid-19 related death after primary
- 197 immunization was high or moderate (Pfizer-BioNTech: 81.5%, Moderna: 93.2%, Sputnik-V:
- 198 100.0%, AstraZeneca: 84.8%, Sinopharm: 58.6%, Janssen: 53.3%). Vaccine effectiveness decreased
- 199 to 60.2% for the Pfizer-BioNTech, 71.9% for the Moderna, 63.0% for the Sputnik-V, and 36.4% for
- 200 the Sinopharm vaccines by >240 days after the completion of primary immunization. All types of
- 201 booster vaccines restored effectiveness up to almost 100% (95.8% to 100.00% for the Pfizer-
- 202 BioNTech booster, 97.0% to 98.2% for the Moderna booster and 94.2% to 100.00% for the Janssen
- 203 booster depending on prior vaccine types), except for the Sinopharm booster (55.3% after 2 doses of
- 204 AstraZeneca to 86.8% after 2 doses of Sinopharm) (Figure 2C, Supplementary Table 7).
- 205 In the age group of 18-64 years, vaccine effectiveness against Covid-19 related death was somewhat
- 206 higher than in the 65–100 years age group. Similarly to the older population, the Sinopharm and
- 207 Janssen vaccines showed lower effectiveness compared to other vaccine types. The patterns of
- 208 waning were very similar in the two age groups, with slightly less waning in terms of Covid-19
- 209 related hospitalization and mortality (Figure 1, Supplementary Table 6).

#### 210 4 Discussion

- 211 We found lower vaccine effectiveness against the Delta variant (B.1.617.2) within the first 4 months
- 212 after primary immunization compared to effectiveness rates reported by the HUN-VE 1 study for
- 213 spring 2021 against the Alpha variant (B.1.1.7) (1), although the results are not directly comparable.
- 214 The lower effectiveness of globally available vaccine types against the Delta variant compared to
- 215 Alpha has been widely reported (15,15,17,18,19). Our study is among the first to report effectiveness
- 216 data for the Sinopharm, Sputnik-V, and Janssen vaccines against the Delta variant, showing a lower
- 217 benefit for Janssen and Sinopharm compared to other vaccine types.
- 218 Most vaccine types provided sustained protection and high effectiveness against Covid-19 related
- 219 death and hospitalization even after only two doses, which is in line with previous publications
- 220 (20,21). A recent prospective study from the United States reported similar, 85% effectiveness of
- 221 mRNA vaccines against Covid-19 related hospitalization among patients infected with the Delta or 222
- Alpha SARS-CoV-2 variant after two doses (20). In a study conducted in the United Arab Emirates
- 223 (UAE), the Sinopharm and Pfizer-BioNTech vaccines provided 95% and 98% effectiveness against 224 Covid-19 related hospitalization in patients infected with the Delta variant, respectively (22). We
- 225 found high protection against mortality of Pfizer-BioNTech, Moderna, Sputnik-V, and AstraZeneca
- 226 vaccines but lower than 60% effectiveness for the Janssen and Sinopharm vaccines during the Delta
- 227 wave in these age groups.
- 228 Waning effectiveness was observed for all outcomes, mostly for protection against SARS-CoV-2
- 229 infection, especially 6 months after primary immunization. The waning of vaccine effectiveness after
- 230 primary immunization is widely discussed (23.24), and in most cases it is attributed to the time-
- 231 dependent decrease of neutralizing response against the SARS-CoV-2 virus. However, most studies
- 232 have reported maintained and only slightly decreased protection against severe outcomes (4,5,6,25).
- 233 There have been very few comparative studies on Sinopharm and other vaccines. The Pfizer vaccine
- 234 was found to be superior to Sinopharm with respect to post-vaccination quantitative antibody titers
- 235 (26). Similarly, the Sputnik V vaccine was also more immunogenic compared to Sinopharm (27).
- 236 Regarding the Omicron variant, both Sinopharm and Janssen yielded significantly lower neutralizing

**Running Title** 

activities compared to Pfizer and Moderna, (28) and, this may explain that in our study, these
vaccines showed a steeper decrease in efficacy over time.

239 Improved protection against all Covid-19 related outcomes with booster vaccines compared to 240 primary immunization has been demonstrated by a number of studies (9,10,11). In a recently 241 published preprint of HUN-VE 2 study from Hungary, booster vaccination provided 96% vaccine 242 effectiveness against SARS-CoV-2 related death as an overall result in comparison to those, having 243 only primary immunization during the Delta wave, where these VE was only 73% (29). Another 244 study from Israel was among the first to report a 93% lower risk of Covid-19 related hospitalization 245 and an 81% lower risk of Covid-19 related death among patients who had received three doses of the 246 Pfizer-BioNTech vaccine compared to those who had received only two doses at least 5 months 247 earlier (30). Later, another Israeli study confirmed the mid-term benefit of booster vaccination with 248 the Pfizer-BioNTech vaccine in the older population (50 years or older), with an adjusted hazard ratio 249 of 0.10 for Covid-19 related death after the third dose vs. primary immunization (11). In a phase 1/2250 clinical trial, adults who had received the Pfizer-BioNTech, Janssen, or Moderna vaccine at least 12 251 weeks prior to enrolment had a 4.2 to 76-fold increase in neutralizing activity against a D614G 252 pseudovirus, and a 4.6 to 56-fold increase in binding antibody titers with all vaccine combinations. 253 Homologous booster doses resulted in a 4.2 to 20-fold increase in neutralizing antibody titers, while 254 heterologous boosters increased titers 6.2 to 76-fold (12). The benefit of booster doses was later 255 confirmed by the VISION Network providing vaccine effectiveness data against Covid-19-associated 256 emergency department and urgent care encounters or hospitalizations during the Delta and Omicron waves (31). In a robust cohort study from the United Kingdom (U.K.), booster vaccination with 257 258 mRNA vaccines provided 85% to 95% relative effectiveness against symptomatic Covid-19 infection 259 and 97% to 99% absolute effectiveness against hospitalization in all age groups during the Delta 260 wave, irrespective of the primary course, with no sign of waning for up to 10 weeks (32). In line with 261 these observations, our study also demonstrated very high effectiveness against infection with the 262 Delta variant for mRNA booster vaccines during the first 4 months irrespective of the type of the 263 primary immunization, and very high, almost 100% effectiveness against Covid-19 related 264 hospitalization and death. Our results harmonized and partially explained by a recently published 265 Hungarian study, where administering a third dose of BNT162b2 (Pfizer-BioNTech) vaccine 266 following two doses of Sinopharm vaccines provided a significantly enhance both humoral and T 267 cell-mediated immune response, and its effectiveness was comparable to three doses of BNT162b2 268 vaccines (33).

On the other hand, our study showed less improvement in adjusted vaccine effectiveness after the Sinopharm booster against SARS-CoV-2 infection and Covid-19 related hospitalization and death both in younger and older age groups. Limited data are available on the benefit of the Sinopharm vaccine as a booster option. Two Chinese study demonstrated the safety and high immunogenicity of a third, homologous Sinopharm vaccination among healthy adults (34,35). To our knowledge, this is the first on the effectiveness of the Sinopharm booster against SARS-CoV-2 infection and Covid-19 related hospitalization and death, particularly in comparison with mRNA vaccine boosters.

276 Although few people received Janssen booster vaccine, we were still able to examine its

effectiveness. It proved to be highly effective against SARS-CoV-2 infection as well as against

278 Covid-19 related hospitalization and death, with similar protection to mRNA boosters irrespective of 279 the type of the primary vaccination. Because only few people received AstraZeneca or Sputnik-V

boosters in our study, we were not able to assess the effectiveness of these combinations.

281 The strengths of our study include its nationwide nature inclusion of six different vaccines as primary

- or booster immunization, the robust number of more than 6 million vaccinated individuals, the 4
- different time frames for the evaluation of waning effectiveness after primary vaccination, the 3

284 different outcomes, and the adjustment for the history of chronic diseases.

285 However, despite adjustments for age, sex, calendar day, and chronic diseases, further important 286 covariates such as medications or socio-economic status were not included in the analysis. The latter 287 could be related to differences in the likelihood of seeking SARS-CoV-2 testing, chance of detection, 288 uptake of vaccines, prognosis of Covid-19, thus may also have resulted in residual confounding. 289 Furthermore, the diagnosis of SARS-CoV-2 infection could also be established based on clinical 290 symptoms, which might have resulted in differential misclassification, somewhat overestimating 291 vaccine efficacy because physicians might have been less likely to diagnose Covid-19 in vaccinated 292 individuals. On the other hand, misclassification might have biased the results in the other direction 293 (i.e., underestimation of vaccine efficacy), as well, regarding the first infection as outcome, as the 294 proportion of unregistered cases were likely to be higher among the unvaccinated population due to 295 the higher incidence among them. Because of the issue of unregistered cases, we did not censor 296 patients with registered infection in the analysis of the risk of hospitalization and death. As the 297 proportion of individuals with natural immunity were likely to be higher in the unvaccinated 298 population, our estimates can be considered conservative in respect of hospitalization and death. 299 Importantly, vaccine effectiveness was demonstrated when the Delta SARS-CoV-2 variant 300 (B.1.617.2) was the dominant strain in Hungary, therefore, the results do not represent the 301 effectiveness of investigated vaccines against the Omicron variant (B.1.1.529) or against new, 302 upcoming variants.

303 In conclusion, the nationwide HUN-VE 3 study provides a comprehensive overview of the durability

304 and effectiveness of SARS-CoV-2 vaccines against infection, Covid-19 related hospitalization and

305 mortality with six different vaccine types used for primary immunization and booster doses after

- 306 primary immunization with various vaccine types. We found significantly waning vaccine
- 307 effectiveness after primary immunization with each vaccine type, especially against SARS-CoV-2
- 308 infection and to a lesser degree against severe Covid-19 related outcomes. On the other hand, our

309 study demonstrates the outstanding benefit of mRNA and Janssen booster vaccines against all Covid-

310 19 related outcomes, irrespective of previously administered vaccine types.

# 311 **5 References**

312 1. Vokó, Z., Kiss, Z., Surján, G., Surján, O., Barcza, Z., Pályi, B., Formanek-Balku, E., Molnár,

G. A., Herczeg, R., Gyenesei, A., Miseta, A., Kollár, L., Wittmann, I., Müller, C., & Kásler, M.

314 (2022). Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study.

315 Clinical microbiology and infection : the official publication of the European Society of Clinical

- 316 Microbiology and Infectious Diseases, 28(3), 398–404. https://doi.org/10.1016/j.cmi.2021.11.011
- 2. Tartof, S. Y., Slezak, J. M., Fischer, H., Hong, V., Ackerson, B. K., Ranasinghe, O. N.,

318 Frankland, T. B., Ogun, O. A., Zamparo, J. M., Gray, S., Valluri, S. R., Pan, K., Angulo, F. J., Jodar,

L., & McLaughlin, J. M. (2021). Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6

320 months in a large integrated health system in the USA: a retrospective cohort study. Lancet (London,

321 England), 398(10309), 1407–1416.

Chemaitelly, H., Tang, P., Hasan, M. R., AlMukdad, S., Yassine, H. M., Benslimane, F. M.,
 Al Khatib, H. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., Al Kuwari, E., Jeremijenko, A.,

324 Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul Rahim, H. F., Nasrallah, G. K., Al Kuwari, M.

325 G., Al Romaihi, H. E., Butt, A. A., ... Abu-Raddad, L. J. (2021). Waning of BNT162b2 Vaccine 326 Protection against SARS-CoV-2 Infection in Qatar. The New England Journal of Medicine, 385(24), 327 e83.

328 4. Goldberg, Y., Mandel, M., Bar-On, Y. M., Bodenheimer, O., Freedman, L., Haas, E. J., Milo, 329 R., Alroy-Preis, S., Ash, N., & Huppert, A. (2021). Waning Immunity after the BNT162b2 Vaccine 330 in Israel. The New England Journal of Medicine, 385(24), e85.

331 5. Cohn, B. A., Cirillo, P. M., Murphy, C. C., Krigbaum, N. Y., & Wallace, A. W. (2022). 332 SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. Science (New York, 333 N.Y.), 375(6578), 331–336.

334 CH. Hansen, AB. Schelde, IR. Moustsen-Helm, HD. Emborg, TG. Krause, K. Mølbak, P. 6. 335 Valentiner-Branth. Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta 336 variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish 337 cohort study. medRxiv 2021.12.20.21267966; doi: https://doi.org/10.1101/2021.12.20.21267966

338 7. Barda, N., Dagan, N., Cohen, C., Hernán, M. A., Lipsitch, M., Kohane, I. S., Reis, B. Y., & 339 Balicer, R. D. (2021). Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for 340 preventing severe outcomes in Israel: an observational study. Lancet (London, England), 398(10316), 341 2093-2100.

342 8. Arbel, R., Hammerman, A., Sergienko, R., Friger, M., Peretz, A., Netzer, D., & Yaron, S. 343 (2021). BNT162b2 Vaccine Booster and Mortality Due to Covid-19. The New England Journal of 344 Medicine, 385(26), 2413–2420.

345 9. CH. Hansen, AB. Schelde, IR. Moustsen-Helm, HD. Emborg, TG. Krause, K. Mølbak, P. 346 Valentiner-Branth. Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta 347 variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish 348 cohort study. medRxiv 2021.12.20.21267966; doi: https://doi.org/10.1101/2021.12.20.21267966

349 10. Barda, N., Dagan, N., Cohen, C., Hernán, M. A., Lipsitch, M., Kohane, I. S., Reis, B. Y., & 350 Balicer, R. D. (2021). Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for 351 preventing severe outcomes in Israel: an observational study. Lancet (London, England), 398(10316), 352 2093-2100.

Arbel, R., Hammerman, A., Sergienko, R., Friger, M., Peretz, A., Netzer, D., & Yaron, S. 353 11. 354 (2021). BNT162b2 Vaccine Booster and Mortality Due to Covid-19. The New England Journal of 355 Medicine, 385(26), 2413–2420.

- 356 12. Koronavirus.gov.hu site – official site of Hungarian Government:
- 357 https://koronavirus.gov.hu/cikkek/magyarorszag-az-elso-ahol-mar-harmadik-oltasra-lehet-idopontot-358 foglalni
- 359 European Commission Directorate-General For Health And Food Safety. EU health 13.
- preparedness: A common list of COVID-19 rapid antigen tests and a common standardised set of 360 361 data to be included in COVID-19 test result certificates. Available at:
- 362 https://ec.europa.eu/health/sites/default/files/preparedness\_response/docs/covid-19\_rat\_common-
- 363 list en.pdf [accessed 3 October 2021]

- 364 14. World Health Organization. (2020). International guidelines for certification and
- 365 classification (coding) of COVID-19 as cause of death.
- 366 www.who.int/classifications/icd/Guidelines\_Cause\_of\_Death\_COVID-19.pdf. Date last updated: 16
- April 2020. Date last accessed: 19 August 2021.

368 15. Puranik, A., Lenehan, P. J., Silvert, E., Niesen, M., Corchado-Garcia, J., O'Horo, J. C., Virk,

- A., Swift, M. D., Halamka, J., Badley, A. D., Venkatakrishnan, A. J., & Soundararajan, V. (2021).
- 370 Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and
- 371 Delta variant prevalence. medRxiv : the preprint server for health sciences, 2021.08.06.21261707.
- 372 https://doi.org/10.1101/2021.08.06.21261707
- Hayawi, K., Shahriar, S., Serhani, M. A., Alashwal, H., & Masud, M. M. (2021). Vaccine
  versus Variants (3Vs): Are the COVID-19 Vaccines Effective against the Variants? A Systematic
- 375 Review. Vaccines, 9(11), 1305. https://doi.org/10.3390/vaccines9111305
- 376 17. Kislaya, I., Rodrigues, E. F., Borges, V., Gomes, J. P., Sousa, C., Almeida, J. P., Peralta-
- 377 Santos, A., Nunes, B., & PT-COVID-19 Group (2022). Comparative Effectiveness of Coronavirus
- 378 Vaccine in Preventing Breakthrough Infections among Vaccinated Persons Infected with Delta and
- Alpha Variants. Emerging infectious diseases, 28(2), 331–337.
- 380 https://doi.org/10.3201/eid2802.211789

18. Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe,
J., Tessier, E., Groves, N., Dabrera, G., Myers, R., Campbell, C., Amirthalingam, G., Edmunds, M.,
Zambon, M., Brown, K. E., Hopkins, S., Chand, M., & Ramsay, M. (2021). Effectiveness of CovidVaccines against the B.1.617.2 (Delta) Variant. The New England Journal of Medicine, 385(7),
585–594. https://doi.org/10.1056/NEJMoa2108891

Sheikh, A., McMenamin, J., Taylor, B., Robertson, C., & Public Health Scotland and the
EAVE II Collaborators (2021). SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital
admission, and vaccine effectiveness. Lancet (London, England), 397(10293), 2461–2462.
https://doi.org/10.1016/S0140-6736(21)01358-1

- Lauring, A. S., Tenforde, M. W., Chappell, J. D., Gaglani, M., Ginde, A. A., McNeal, T.,
  Ghamande, S., Douin, D. J., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., Shapiro, N. I.,
  Gibbs, K. W., Files, D. C., Hager, D. N., Shehu, A., Prekker, M. E., Erickson, H. L., Exline, M. C.,
  Influenza and Other Viruses in the Acutely III (IVY) Network (2022). Clinical severity of, and
  effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2
  variants in the United States: prospective observational study. BMJ (Clinical research ed.), 376,
  e069761. https://doi.org/10.1136/bmj-2021-069761
- Fiolet, T., Kherabi, Y., MacDonald, C. J., Ghosn, J., & Peiffer-Smadja, N. (2022). Comparing
  COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and
  variants of concern: a narrative review. Clinical microbiology and infection : the official publication
  of the European Society of Clinical Microbiology and Infectious Diseases, 28(2), 202–221.
  https://doi.org/10.1016/j.cmi.2021.10.005

402 22. Mousa, M., Albreiki, M., Alshehhi, F., AlShamsi, S., Marzouqi, N. A., Alawadi, T., Alrand,
403 H., Alsafar, H., & Fikri, A. (2022). Similar effectiveness of the inactivated vaccine BBIBP-CorV
404 (Sinopharm) and the mRNA vaccine BNT162b2 (Pfizer-BioNTech) against COVID-19 related

405 hospitalizations during the Delta outbreak in the United Arab Emirates. Journal of Travel Medicine, 406 taac036. Advance online publication. https://doi.org/10.1093/jtm/taac036

407 23. Levine-Tiefenbrun, M., Yelin, I., Alapi, H., Katz, R., Herzel, E., Kuint, J., Chodick, G., Gazit,

408 S., Patalon, T., & Kishony, R. (2021). Viral loads of Delta-variant SARS-CoV-2 breakthrough 409 infections after vaccination and booster with BNT162b2. Nature Medicine, 27(12), 2108–2110.

410 https://doi.org/10.1038/s41591-021-01575-4

411 24. Pouwels, K. B., Pritchard, E., Matthews, P. C., Stoesser, N., Eyre, D. W., Vihta, K. D.,

412 House, T., Hay, J., Bell, J. I., Newton, J. N., Farrar, J., Crook, D., Cook, D., Rourke, E., Studley, R.,

413 Peto, T., Diamond, I., & Walker, A. S. (2021). Effect of Delta variant on viral burden and vaccine

414 effectiveness against new SARS-CoV-2 infections in the UK. Nature Medicine, 27(12), 2127–2135. 415 https://doi.org/10.1038/s41591-021-01548-7

416 Tang, P., Hasan, M. R., Chemaitelly, H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. 25.

417 A., AlMukdad, S., Coyle, P., Ayoub, H. H., Al Kanaani, Z., Al Kuwari, E., Jeremijenko, A.,

418 Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul Rahim, H. F., Nasrallah, G. K., Al Kuwari, M.

- 419 G., Al Romaihi, H. E., Butt, A. A., ... Abu-Raddad, L. J. (2021). BNT162b2 and mRNA-1273
- COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nature Medicine, 420
- 421 27(12), 2136–2143. https://doi.org/10.1038/s41591-021-01583-4

422 26. Alqassieh, R., Suleiman, A., Abu-Halaweh, S., Santarisi, A., Shatnawi, O., Shdaifat, L.,

423 Tarifi, A., Al-Tamimi, M., Al-Shudifat, A. E., Alsmadi, H., Al Sharqawi, A., Alnawaiseh, H.,

424 Anasweh, Y., Domaidah, F. A., Jaber, H. A., Al-Zarir, M. R., & Bsisu, I. (2021). Pfizer-BioNTech

425 and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers. Vaccines, 9(11), 1223. 426 https://doi.org/10.3390/vaccines9111223

427 27. Stoma I, Korsak K, Voropaev E, Osipkina O, Kovalev A. Comparative study of 428 immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines in Belarus. 429 medRxiv 2022.02.05.22270499; doi: https://doi.org/10.1101/2022.02.05.22270499

430 28. Cameroni E, Saliba C, Bowen JE, Rosen LE, Culap K, Pinto D et al. Broadly neutralizing 431 antibodies overcome SARS-CoV-2 Omicron antigenic shift. bioRxiv 2021.12.12.472269; doi: 432 https://doi.org/10.1101/2021.12.12.472269

- 433 29. Kiss Z, Wittmann I, Polivka L, Surján Gy, Surján O, Barcza Zs. Kassler M at al. Nationwide 434 Effectiveness of First and Second SARS-CoV2 Booster Vaccines during the Delta and Omicron 435 Pandemic Waves in Hungary (HUN-VE 2 Study). medRxiv 2022.03.27.22273000; doi:
- 436 https://doi.org/10.1101/2022.03.27.22273000

437 30. Barda, N., Dagan, N., Cohen, C., Hernán, M. A., Lipsitch, M., Kohane, I. S., Reis, B. Y., & 438 Balicer, R. D. (2021). Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for 439 preventing severe outcomes in Israel: an observational study. Lancet (London, England), 398(10316), 440 2093-2100. https://doi.org/10.1016/S0140-6736(21)02249-2

441 31. Ferdinands JM, Rao S, Dixon BE, et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA

442 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and

443 Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance -

444 VISION Network, 10 States, August 2021–January 2022. MMWR Morb Mortal Wkly Rep

445 2022;71:255–263. DOI: http://dx.doi.org/10.15585/mmwr.mm7107e2external icon.

Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Sachdeva, R., Gower, C., Ramsay, M., &
Lopez Bernal, J. (2022). Effectiveness of COVID-19 booster vaccines against COVID-19-related
symptoms, hospitalization and death in England. Nature Medicine, 10.1038/s41591-022-01699-1.
Advance online publication. https://doi.org/10.1038/s41591-022-01699-1

450 33. Matula, Z., Gönczi, M., Bekő, G., Kádár, B., Ajzner, É., Uher, F., Vályi-Nagy, I. Antibody
451 and T cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm)
452 and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster
453 Vaccinetion Strategy, Vaccines 2022, 10, 530, https://doi.org/10.2200/vaccines10040530

453 Vaccination Strategy. Vaccines 2022, 10, 539. https://doi.org/10.3390/ vaccines10040539

454 34. Ai, J., Zhang, Y., Zhang, H., Zhang, Q., Fu, Z., Lin, K., Song, J., Zhao, Y., Fan, M., Wang,
455 H., Zhou, Y., Chen, X., Qiu, C., & Zhang, W. (2022). Safety and immunogenicity of a third-dose
456 homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study.

457 Emerging Microbes & Infections, 11(1), 639–647. https://doi.org/10.1080/22221751.2022.2025746

458 35. Zhang, Y., Yang, Y., Qiao, N., Wang, X., Ding, L., Zhu, X., Liang, Y., Han, Z., Liu, F.,

- 459 Zhang, X., & Yang, X. (2022). Early assessment of the safety and immunogenicity of a third dose
- 460 (booster) of COVID-19 immunization in Chinese adults. Frontiers in Medicine, 1–9. Advance online
   461 publication. https://doi.org/10.1007/s11684-021-0914-x

## 462 6 Conflict of Interest

463 Zsófia Barcza of Syntesia Medical Communications Ltd. received payment for medical writing

464 support from the National Public Health Center of Hungary. Zoltán Kiss is employed by MSD

465 Pharma Hungary Ltd., too. However, this provides no relevant conflict of interest for the current

466 research. At the time the study was performed, M.K served as the minister of human resources. The

467 *ministry includes the secretariat for health.* 

## 468 **7** Author Contributions

469 Z Vokó: Conceptualization, Methodology, Formal analysis, Validation and Writing – Review &

470 Editing; Z Kiss and I Wittmann: Conceptualization, Methodology, Investigation, Visualization and

471 Writing – Original Draft; L Polivka Conceptualization, Methodology, Formal analysis, Validation,

472 Data curation; Gy Surján, P Nagy, I Kenessey, A Wéber: Conceptualization, Methodology,

473 Validation, Review & Editing; D Nagy, Gy. Rokszin: Conceptualization, Methodology, Formal

474 analysis; O Surján, V Müller, Z Szekanecz, J Szlávik: Conceptualization, Review & Editing; M

475 Kásler, C Müller: Conceptualization, Methodology, Investigation and Supervision; Zs Barcza:

476 Writing – Original Draft; GA Molnár: Validation, Project Administration

# 477 **8 Funding**

478 The Center for Health Technology Assessment of the Semmelweis University participated in the

479 project on a contractual basis made with the Ministry of Human Resources of Hungary and received

480 funding. Zsófia Barcza of Syntesia Medical Communications Ltd. received payment for medical

481 writing support from the National Public Health Center of Hungary.

# 482 9 Acknowledgments

483 The authors would like to thank Richárd Kiss for the initial data curation and dataset validation.

### **Running Title**

#### 484 10 Legend to Figures

- 485 Figure 1 Adjusted vaccine effectiveness against registered SARS-CoV-2 infection, Covid-19 related
- 486 hospitalization and death during the Delta wave in the Hungarian population aged 16–64 years.
- 487 \*Datapoints marked with triangles at value 100% indicate vaccine combination categories where no 488 outcome occurred. In these categories, the person-time of observation is very limited.
- 489 Figure 2 Adjusted vaccine effectiveness against registered SARS-CoV-2 infection, Covid-19 related
- 490 hospitalization and death during the Delta wave in the Hungarian population aged 65–100 years.
- 491 \*Datapoints marked with triangles at value 100% indicate vaccine combination categories where no
- 492 outcome occurred. In these categories, the person-time of observation is very limited.

#### 493 11 **Data Availability Statement**

494 The datasets generated for this study can be found in the MedRxiv repository. Further inquiries can 495 be directed to the corresponding author.

#### 496 12 Contribution to the field statement

497 Vaccines became the cornerstone of defense against Covid-19, especially as lockdown measures 498 needed to be eased. In a previous study (HUN-VE 1) we investigated vaccine efficacy of five 499 different vaccines (mRNA-based, subunit-based and inactivated virus-based vaccines) during the 500 alpha wave. In the present paper, we analyze vaccine effectiveness (in terms of infection, 501 hospitalization, and mortality) in primary immunized and first boostered groups of cases during the 502 delta wave using nationwide data from Hungary related to six vaccine types (Pfizer-BioNTech, 503 Moderna, Sputnik-V, AstraZeneca, Sinopharm and in this paper also the Janssen vaccine). We show 504 waning of the protection over time with all vaccines used for primary vaccination. Different 505 combination of primary vaccinations and boosters were effective in a different manner (with 506 Sinopharm and Janssen vaccines somewhat less effective in most aspects). Overall, most boosters 507 restored vaccine effectiveness to nearly 100% in case of Covid-related hospitalization and Covid-508 related mortality. The strengths of our study are, that it provides nationwide data, it enables 509 comparison of primary vaccinated vs. boostered groups, and that it enables comparison of six 510 different vaccine types. Furthermore, cases with age < 65 or >65 years could be separately analyzed, 511 providing data on vaccine effectiveness in the elderly.



